Gain Therapeutics, Inc. (GANX)

Gain Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6.69	10.39	11.79	7.31	36.88	7.49
Short-Term Investments	-	-	5	12.83	-	-
Cash & Short-Term Investments	6.69	10.39	16.79	20.14	36.88	7.49
Cash Growth	-60.48%	-38.16%	-16.61%	-45.40%	392.21%	2370.30%
Accounts Receivable	-	-	-	-	-	0.01
Other Receivables	0.32	0.77	0.24	0.19	0.2	0.06
Receivables	0.32	0.77	0.24	0.19	0.2	0.07
Prepaid Expenses	2.29	0.45	0.74	0.76	0.65	0.2
Restricted Cash	-	-	-	-	-	0.01
Other Current Assets	-	-	-	-	-	1.22
Total Current Assets	9.31	11.6	17.78	21.09	37.72	8.99
Property, Plant & Equipment	0.33	0.32	0.59	0.8	1.01	0.55
Long-Term Investments	-	-	-	1.94	-	-
Other Intangible Assets	0.13	0.13	0.19	0.21	0.2	-
Other Long-Term Assets	0.07	0.06	0.05	0.05	0.05	0.06
Total Assets	9.83	12.12	18.61	24.1	38.99	9.6
Accounts Payable	2.71	0.95	1.32	1.63	0.56	0.96
Accrued Expenses	-	2.42	2.11	2	1.4	0.76
Current Portion of Long-Term Debt	0.13	0.11	0.12	0.11	0.1	0.02
Current Portion of Leases	0.14	0.16	0.23	0.23	0.22	0.12
Current Income Taxes Payable	-	0.02	0.05	0.11	0	0
Current Unearned Revenue	0.02	0.25	1.12	0.06	0.27	0.24
Other Current Liabilities	2.2	-	-	-	-	0.01
Total Current Liabilities	5.2	3.91	4.95	4.13	2.55	2.11
Long-Term Debt	0.33	0.33	0.45	0.5	0.59	0.72
Long-Term Leases	0.09	0.05	0.23	0.44	0.7	0.4
Long-Term Unearned Revenue	-	0.05	0.09	-	-	-
Total Liabilities	6.14	4.78	6.03	5.22	4.17	3.4
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	94.64	88.78	73.11	57.36	55.83	13.39
Retained Earnings	-91.53	-81.19	-60.78	-38.52	-20.93	-7.03
Comprehensive Income & Other	0.58	-0.25	0.25	0.04	-0.09	-0.15
Total Common Equity	3.7	7.34	12.58	18.88	34.82	6.2
Shareholders' Equity	3.7	7.34	12.58	18.88	34.82	6.2
Total Liabilities & Equity	9.83	12.12	18.61	24.1	38.99	9.6
Total Debt	0.68	0.65	1.03	1.27	1.61	1.26
Net Cash (Debt)	6.01	9.73	15.77	20.81	35.27	6.23
Net Cash Growth	-62.72%	-38.27%	-24.22%	-41.01%	466.03%	5987.28%
Net Cash Per Share	0.21	0.43	1.21	1.75	3.47	2.32
Filing Date Shares Outstanding	30.77	27.79	16.22	11.88	11.88	4.02
Total Common Shares Outstanding	30.77	27.13	16.21	11.88	11.88	4.02
Working Capital	4.11	7.69	12.83	16.97	35.17	6.87
Book Value Per Share	0.12	0.27	0.78	1.59	2.93	1.54
Tangible Book Value	3.57	7.21	12.38	18.67	34.61	6.2
Tangible Book Value Per Share	0.12	0.27	0.76	1.57	2.91	1.54
Machinery	-	0.2	0.18	0.17	0.12	0.03
Leasehold Improvements	-	0.03	0.03	0.03	0.02	0.01

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q